Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Date:3/13/2009

p>

The poster presentation will also include data describing the similar anti-tumor effects of nimotuzumab and cetuximab against EGFR-overexpressing tumors. Nimotuzumab's requirement for bivalent binding (similar to conditions that make Herceptin(R) effective), limits the accumulation of nimotuzumab to tissues with higher EGFR density (principally occuring in tumors).

"This research, together with the accumulating clinical data on nimotuzumab, demonstrate that, where tumors over-express EGFR naturally, or are stimulated to over-express EGFR by radiation-containing regimens, nimotuzumab would be expected to have similar efficacy to Erbitux(R) and Vectibix(R)," explained David Allan.

The authors conclude that toxicities of Erbitux(R) should not be viewed as markers for clinical benefit of EGFR-targeting antibodies in general, but only as markers of indiscriminate targeting of that particular antibody, with the EGFR blockade of normal cells by the marketed antibodies disrupting the cell's function. This finding is especially important in view of the recent papers describing the underreporting of the toxicities of Erbitux(R), particularly Grade IV radiation dermatitis in head and neck cancer, reportedly not previously observed with radiation alone. These presentations by YM help to demonstrate the nature of differentiation of nimotuzumab from the other anti-EGFR antibodies and show that its intrinsic properties confer a wide therapeutic window compared to Erbitux(R) and thus, in contrast to it, nimotuzumab is a more precisely targeted therapy.

The AACR abstract builds on a presentation by YM at the AACR Translational Medicine conference held in June 2008, which demonstrated that, in tumor cells expressing moderate-to-high levels of the EGF receptor, nimotuzumab has binding equivalent to the currently marketed EGFR-targeting antibodies. The AACR 2009 presentation includes data demonstrating equivalent anti-tumor effects of nimotuzumab and cetu
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
2. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
3. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
4. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
5. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
11. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Calif. , Oct. 1, 2014  Varian Medical ... it will report results for the fourth quarter of ... on Wednesday, October 22, 2014.  The news release will ... parties at 2:00 p.m. PT.  The news release and ... available on the company website at: www.varian.com/investor .  ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
(Date:10/1/2014)... FREMONT, Calif. , Oct. 1, 2014 ... ARDX ), a clinical-stage biopharmaceutical company focused ... announced positive results from its 371 patient ... patients with constipation-predominant irritable bowel syndrome (IBS-C).  ... and clinically meaningful improvement in IBS-C symptoms ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
(Date:10/1/2014)... October 01, 2014 T.E.N., ... and relationship-marketing firm, announced today the nominees ... and Project of the Year Awards for ... representing organizations in financial services, commercial, health ... technology endeavors that address key issues in ...
(Date:10/1/2014)... MO (PRWEB) October 01, 2014 Join the ... Castlewood Eating Disorder Treatment Center’s first ever charity golf tournament ... for people with eating disorders who cannot afford treatment. The ... Golf Club in Eureka, Mo. , The day-long event ... noon. A reception and award dinner will begin at 5 ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... Cancer,Center announced that Judy and Larry Freeman have ... Comprehensive Cancer Center, Keck School of,Medicine of USC. ... Freeman Cancer,Day Hospital, an outpatient facility currently located ... Larry Freeman is the founder of Freeman,Cosmetics Corporation, ...
... contains minerals that provide safe, effective prevention,and relief from ... 23 Dr. Howard Peiper, a Pulitzer prize,nominated author, ... 12 best sellers. Dr. Peiper is recommending a brand ... Zeolite-AV,and is the first all natural product ever created ...
... do not routinely remove cancer from the lungs may be ... conducted by researchers at Duke University Medical Center. , "Our ... types of surgeries have correspondingly lower mortality rates than those ... an anesthesiologist at Duke and lead investigator on the study. ...
... to end the symptoms of her diabetes. Jeannie Baellow, 54, was chosen ... the Lifestyle Center of America (LCA). , ... New York, NY (PRWEB) ... fight to end the symptoms of her diabetes. Jeannie Baellow, 54, was ...
... Oct. 22 Every year in Jacksonville,nearly 600 ... until now,their long road to recovery lacked long-term ... Clubhouse, the only program,in Florida created to help ... to community reintegration., The Brain Injury Association ...
... to Steal, SAN FRANCISCO, Oct. 22 ... identity theft, and in a lawsuit filed against ... claims that the,credit industry is facilitating the crimes. ... identity verification systems, credit,card companies such as Bank ...
Cached Medicine News:Health News:USC Cancer Center Announces Contribution By Larry and Judy Freeman 2Health News:Doctor Recommends New Powerful Natural Antiviral Against the Flu 2Health News:Doctor Recommends New Powerful Natural Antiviral Against the Flu 3Health News:Study finds that practice makes perfect in lung cancer surgery 2Health News:Video Blog Chronicles One Woman's Fight Against Her Diabetes 2Health News:Brooks Rehabilitation Opens First Work-Based Brain Injury Rehab Program in Florida 2Health News:Credit Card Companies Accomplices in Millions of Identity Theft Cases Alleges Eric Drew 2
... Normal and Abnormal Control ... of vWF, D-dimer and ... STA© Analyzers. For use ... (#0518),STA© LIATEST© D-DI (#0515) ...
CRP Full Range (0.1-160mg/l)...
Inquire...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Medicine Products: